This three-group, single-blind clinical trial study was conducted on a sample of children admitted to the Ali Ibn Abi Talib Hospital pediatric ward in Zahedan. The inclusion criteria were the absence of underlying diseases such as diabetes, asthma, and skin diseases and not receiving vancomycin. The exclusion criteria were discharged from the hospital three days before the start of the intervention, unwillingness to continue cooperating in the study, failure to use Aloe vera compress or warm compress during the study, and the patient’s critical condition for any reason.
The sample size was estimated as 19 patients per group based on the mean and standard deviation of the degree of phlebitis (Haji Hosseini et al., (
20)), considering a 95% confidence interval, and 85% test power, using the following formula. Following similar studies and given the probable dropout, a total of 90 patients were selected as the participants in the study (30 patients in each group) (
Figure 1).
Z1-α/2 = 1.96, S1= 0.45, μ = 1.20, Z1-β = 1.03, S2 = 0.9, μ = 0.7.
Before conducting the study, 90 children aged 3 - 8 years who had phlebitis caused by a peripheral vein catheter and met other criteria were selected through convenience sampling. Then, in the second stage, the selected children were randomly divided into three groups: Control, Aloe vera compress intervention, and warm compress intervention groups. For this purpose, 90 colored cards (30 blue colored cards for the Aloe vera intervention group, 30 red colored cards for the warm compress intervention group, and 30 yellow cards for the control group) were placed in a box. Then, each child's mother picked out a colored card from the box with her eyes closed, and the child was assigned to a group based on the color of the card. The pain intensity was first measured for the children in the control group. The parents of all children in the three groups received the necessary instructions about the study's objectives and the research procedure.
The data in this study were collected using a patient demographic information questionnaire and Wong-Baker Faces Pain Rating Scale. The demographic information questionnaire contained 5 items that measured the child's gender, age, current diseases, and any underlying illnesses and skin diseases. The Wong-Baker Faces Pain Rating Scale was developed in 1988 and consists of a card with 6 emoticons marked with a numerical scale (from laughing to crying). The patient, who is usually 3 - 8 years old, chooses one based on the pain's intensity. Then, the intensity of pain is calculated by the researcher. The score range on the scale varies from 0 (no pain) to 10 (severe pain).
The validity and reliability of the Wong-Baker Faces Pain Rating Scale has been confirmed in several studies (
21-
23). The Persian version of this scale has been used in several studies (
24,
25). Nikfarid et al. estimated the correlation coefficient for the scale as equal to 0.82, confirming its validity (
24). The scale's reliability was assessed in the present study using inter-rater reliability and was confirmed with a coefficient of 0.79. The demographic information questionnaire was completed by interviewing the parents and using the data in patients’ medical records. Moreover, the pain intensity was measured using the Wong-Baker Faces Pain Rating Scale, and the related values were recorded in a form. The equipment used in this study consisted of a heat gel pack,
Aloe vera gel (Kaman Brand, Seilaneh Sabz Company), cotton bandage, sterile gauze, and a digital thermometer.
Before starting the intervention, the pain intensity in the children was measured and recorded using the Wong-Baker Faces Pain Rating Scale. Then, after disinfecting the phlebitis site, a sterile gauze was soaked in 5 cc of Aloe vera gel, drawn with a syringe, and placed on the child’s phlebitis site in the Aloe vera group, and the place was covered with a bandage for 20 minutes.
In the warm compress group, first, the heat gel pack (model 810 or Sina Hakim) was placed in the microwave for 30 - 60 seconds at a temperature of 800 W (according to the manufacturer’s instructions). Then, the pack was gently taken out with gauze, and its temperature was checked with a digital thermometer to be 37 - 38 degrees Celsius. The pack was covered with sterile gauze and placed on the phlebitis site for 20 minutes. No intervention was performed for the children in the control group, and no special routine procedure was performed to reduce pain caused by phlebitis. Simultaneously with the other two groups, the pain scores for the patients in the control group were measured and recorded.
Pain intensity was measured for the children in the three groups before and after the interventions. The interventions were repeated by the researcher every 12 hours for 3 days. The researcher recorded the pain score every 12 hours before the intervention and on the first, second, and third days. Six interventions were performed for the children in the Aloe vera and warm compress groups. The researcher repeated all intervention times. Pain intensity was recorded and assessed in the pre-intervention stage for the children in all three groups. It was also measured for the warm compress group half an hour after the intervention and for the Aloe vera group at the beginning of the intervention. Data analysis was performed using a blind procedure by a person who knew nothing about the interventions and the groups.
Data analysis was performed using SPSS-22 software. First, the normality of the data was checked using the Shapiro-Wilk test, and since the data followed a normal distribution pattern, parametric tests, including the chi-square test, independent samples t-test, one-way analysis of variance (ANOVA), and Fisher’s exact test were run at a significance level of less than 0.05 (P < 0.05). The present study was conducted based on a research proposal approved with code IR.ZAUMS.REC.1401.059 by the Zahedan University of Medical Sciences and Medical Services Ethics Committee. This research project was registered with the IRCT code (IRCT20220427054677N1) in the Iranian Registry of Clinical Trials.